Clinical Trials at Duke Comprehensive Cancer Center

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Emily Dill, RN at (919) 681-4769.

Trial Phase Lymphomas - Non-Hodgkin's lymphoma and Hodgkin's disease
00001363 II A Phase II Study of EL625 in Patients in Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
00003503 II Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin's Disease
00005405 III CALGB 50102: A Phase III Trial of CHOP vs CHOP+Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) for Treatment of Newly Dx Follicular NHL.
00008487 II A Phase II Study of Bortezomib in Combination with Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (VR-FND) for Relapsed or Refactory Follicular Lymphoma
00010668 III A Phase III Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
00009404 II CALGB 10002: Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with G-CSF Support in Previously Untreated Patients with Burkitt Lymphoma/Leukemia.
00007001 II A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients with Stage I or IIA Mycosis Fungoides (MF)
00012176 Pilot/Feasibility Pilot Study of Sequential Myeloablative Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation Followed by Adoptive Cellular Immunotherapy in Patients with Recurrent/Refractory Non-Hodgkin's Lymphoma and Hodgkin's Disease.
00011268 II An Open-Label, Multi-Center Clinical Trial of HuMax-CD4 in Patients with Mycosis Fungoides Type CTCL (stage Ib-IVb) Who are Refractory or Intolerant to Targretin and Other Standard Therapy
Duke Comprehensive Cancer Center Accolades